The experimental results showed that although NSCLC patients with abnormal EGFR preferred TKI therapy compared to patients with normal EGFR, clinical EGFR-TKI therapy did not have a significant advantage over first-line chemotherapeutic agents in NSCLC patients with abnormal EGFR based on the available data. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.